AFP and hepatocellular carcinoma: Indeed, during the algorithm development study, univariate ROC analysis showed that none of the biomarkers tested met the clinical requirements for early-stage or all-stage HCC detection, with AUC of 83.4% for AFP, 79.0% for PIVKA-II and 76.5% for AFP-L3.22